Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prime Medicine, Inc. (PRME)
NASDAQ:PRME
RESEARCH TOOLSreports
Holding PRME?
Track your performance easily
PRME Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.28 - $9.86
Previous Close$3.35
Volume1.40M
Average Volume (3M)1.49M
Market Cap
$438.73M
Enterprise Value$362.00M
Total Cash (Recent Filing)$117.98M
Total Debt (Recent Filing)$41.25M
Price to Earnings (P/E)―
Beta2.75
Next Earnings
Mar 06, 2025EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding131,160,842
10 Day Avg. Volume1,167,725
30 Day Avg. Volume1,493,259
Standard Deviation0.19
R-Squared0.17
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)2.32
Price to Sales (P/S)487.11
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue373.97
Enterprise Value/Gross Profit2.15K
Enterprise Value/Ebitda-1.84
Forecast
1Y Price Target
$10.83Price Target Upside223.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Prime Medicine, Inc. News
PremiumCompany Announcements
Prime Medicine Reports Q3 2024 Financial Progress
PremiumPre-Earnings
Is PRME a Buy, Before Earnings?
PremiumCompany Announcements
Prime Medicine Advances Gene Editing for Liver Diseases
Bulls Say, Bears Say
Bulls Say
Financial PerformancePrime received $110MN upfront from Bristol Myers Squibb, which includes a $55MN upfront payment and $55MN equity investment, strengthening the company's financial position.
Strategic PartnershipsPrime Medicine formed a multi-billion-dollar partnership with Bristol Myers Squibb to discover, develop, and commercialize next-generation ex vivo T-cell therapies.
Technological InnovationBMS's interest in Prime Editing platform, despite having access to CRISPR-Cas technology, highlights the unique advantages of Prime's technology, such as avoiding double strand breaks in DNA.
Bears Say
Cash FlowThe short cash runway remains an overhang for the company.
Financial PerformancePRME reported a Q3 net loss of $53MM despite the upfront infusion from the research collaboration with BMS.
Market ValuationThe key hold-ups in the editing space in terms of market valuation is the risk around long term safety data in patients and expansion into in vivo settings.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $3.28 and its highest was $9.86 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Currently, no data Available
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 106 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.385 by -$0.055.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. does not currently pay dividends.
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -$0.36.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 131,160,840 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.385. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Among the largest hedge funds holding Prime Medicine, Inc.’s share is ARK Investment Management LLC. It holds Prime Medicine, Inc.’s shares valued at 31M.
---
Prime Medicine, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.83 (223.77% Upside)
$10.83 (223.77% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 83%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 151.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.69%
12-Months-Change
Fundamentals
Return on Equity
-114.35%
Trailing 12-Months
Asset Growth
39.16%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs.
---
PRME Stock 12 Month Forecast
Average Price Target
$10.83
▲(223.77% Upside)
Technical Analysis
Beam Therapeutics
―
Meiragtx Holdings
―
Voyager Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering PRME
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
-4.60%
reiterated a buy rating 8 days ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -4.60% per trade.
---